Dr.Pukhraj Rishi
Aim: To describe the 3 year treatment outcomes and complications of selective intra-arterial chemotherapy (IAC) for intraocular retinoblastoma (RB). Methods: interventional series of 10 eyes with RB which underwent IAC using melphalan (5 mg/7.5 mg) +/- topotecan (1 mg). Treatment outcomes were evaluated in terms of tumor control, vitreous seeds (VS) and subretinal seeds (SRS) control, and globe salvage rates. Results: 10 eyes of 10 patients underwent mean 3.8 IAC sessions (median: 4; range: 3–5 sessions). Complete regression of the main tumor was seen in 9 eyes (90%), and partial regression in 1 eye (10%). Five of 2 eyes (40%) with VS showed complete regression. Three of 4 eyes with SRS (75%) showed complete regression. Globe salvage was achieved in 8 of 10 (80%) eyes. Mean follow-up was 31 months (Median= 33, Range=18-46). Conclusions: IAC is an effective therapy for globe preservation in eyes with intraocular RB.


Leave a Comment